FDA américaine
((Traduction automatisée par Reuters, veuillez consulter la clausede non-responsabilité https://bit.ly/rtrsauto))
La Food and Drug Administrationaméricaine a approuvé le traitement de nouvelle génération deVertex Pharmaceuticals VRTX.O pour une maladie génétique rareet progressive, a déclaré la société vendredi, renforçant ainsisa domination sur le marché de la mucoviscidose.
© 2024 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.
